Olema Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
OLMA$7.27-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
(Amounts in thousands, except for share amounts)
| Accumulated | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||||
| Shares · Amount · Capital · (Loss) Income · Deficit · Equity | |||||||||||
| Balances at December 31, 2025 | 81,376,449 | $ | 8 | $ | 1,075,487 | $ | 621 | $ | (597,557) | $ | 478,559 |
| Exchange of pre-funded warrants for common stock shares | 3,500,000 | — | — | — | — | — | |||||
| Stock-based compensation expense | — | — | 10,148 | — | — | 10,148 | |||||
| Issuance of shares under at-the-market offering, net of issuance costs of $25 | 1,712,739 | — | 41,918 | — | — | 41,918 | |||||
| Exercise of stock options | 743,783 | — | 4,023 | — | — | 4,023 | |||||
| Net unrealized loss on marketable securities | — | — | — | (1,081) | — | (1,081) | |||||
| Net loss | — | — | — | — | (53,089) | (53,089) | |||||
| Balances at March 31, 2026 | 87,332,971 | $ | 8 | $ | 1,131,576 | $ | (460) | (650,646) | $ | 480,478 | |
| Accumulated | |||||||||||
| Additional · Other · Total | |||||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||||
| Shares · Amount · Capital · Income · Deficit · Equity | |||||||||||
| Balances at December 31, 2024 | 74,312,608 | $ | 7 | $ | 843,920 | $ | 143 | (435,106) | $ | 408,964 | |
| Exchange of common stock shares for pre-funded warrants | (6,070,000) | — | — | — | — | — | |||||
| Stock-based compensation expense | — | — | 4,378 | — | — | 4,378 | |||||
| Exercise of stock options | 90,457 | — | 236 | — | — | 236 | |||||
| Issuance costs for the shares issued under equity private placement | — | — | (14) | — | — | (14) | |||||
| Net unrealized gain on marketable securities | — | — | — | 277 | — | 277 | |||||
| Net loss | — | — | — | — | (30,389) | (30,389) | |||||
| Balances at March 31, 2025 | 68,333,065 | $ | 7 | $ | 848,520 | $ | 420 | (465,495) | $ | 383,452 | |
Condensed Consolidated Statements of Cash Flows
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.